Adaptation of colonic fermentation and glucagon-like peptide-1 secretion with increased wheat fibre intake for 1 year in hyperinsulinaemic human subjects - PubMed (original) (raw)
Randomized Controlled Trial
doi: 10.1017/S0007114509991462. Epub 2009 Aug 7.
Affiliations
- PMID: 19664300
- DOI: 10.1017/S0007114509991462
Randomized Controlled Trial
Adaptation of colonic fermentation and glucagon-like peptide-1 secretion with increased wheat fibre intake for 1 year in hyperinsulinaemic human subjects
Kristin R Freeland et al. Br J Nutr. 2010 Jan.
Abstract
High cereal fibre intake is associated with reduced risk for type 2 diabetes, but wheat fibre had little or no effect on glycaemic control or oral glucose tolerance in clinical trials lasting 4-12 weeks. To explain this discrepancy, we hypothesised that colonic adaptation to increased wheat fibre intake takes many months but eventually results in increased SCFA production and glucagon-like peptide-1 (GLP-1) secretion. Thus, the primary objective was to determine the time-course of the effects of increased wheat fibre intake on plasma acetate, butyrate and GLP-1 concentrations in hyperinsulinaemic human subjects over 1 year. Subjects with fasting plasma insulin >or= 40 pmol/l were randomly assigned by computer to receive either a high-wheat fibre cereal (fibre group; 24 g fibre/d; twenty assigned; six dropped out, fourteen included) or a low-fibre cereal (control group; twenty assigned; six dropped-out, fourteen included) daily for 1 year. Acetate, butyrate and GLP-1 were measured during 8 h metabolic profiles performed every 3 months. There were no differences in body weight in the fibre group compared with the control group. After 9 months baseline-adjusted mean 8 h acetate and butyrate concentrations were higher on the high-fibre than the control cereal (P < 0.05). After 12 months on the high-fibre cereal, baseline-adjusted mean plasma GLP-1 was 1.3 (95 % CI 0.4, 2.2) pmol/l (P < 0.05) higher than at baseline (about 25 % increase) and 1.4 (95 % CI 0.1, 2.7) pmol/l (P < 0.05) higher than after 12 months on control. It is concluded that wheat fibre increased SCFA production and GLP-1 secretion in hyperinsulinaemic humans, but these effects took 9-12 months to develop. Since GLP-1 may increase insulin sensitivity and secretion, these results may provide a mechanism for the epidemiological association between high cereal fibre intake and reduced risk for diabetes.
Trial registration: ClinicalTrials.gov NCT00247455.
Similar articles
- Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance.
Vollmer K, Holst JJ, Baller B, Ellrichmann M, Nauck MA, Schmidt WE, Meier JJ. Vollmer K, et al. Diabetes. 2008 Mar;57(3):678-87. doi: 10.2337/db07-1124. Epub 2007 Dec 5. Diabetes. 2008. PMID: 18057091 - Acute effects of intravenous and rectal acetate on glucagon-like peptide-1, peptide YY, ghrelin, adiponectin and tumour necrosis factor-alpha.
Freeland KR, Wolever TM. Freeland KR, et al. Br J Nutr. 2010 Feb;103(3):460-6. doi: 10.1017/S0007114509991863. Epub 2009 Oct 12. Br J Nutr. 2010. PMID: 19818198 - No increased risk of hypoglycaemic episodes during 48 h of subcutaneous glucagon-like-peptide-1 administration in fasting healthy subjects.
Lerche S, Soendergaard L, Rungby J, Moeller N, Holst JJ, Schmitz OE, Brock B. Lerche S, et al. Clin Endocrinol (Oxf). 2009 Oct;71(4):500-6. doi: 10.1111/j.1365-2265.2008.03510.x. Epub 2008 Dec 15. Clin Endocrinol (Oxf). 2009. PMID: 19094067 Clinical Trial. - New hypotheses for the health-protective mechanisms of whole-grain cereals: what is beyond fibre?
Fardet A. Fardet A. Nutr Res Rev. 2010 Jun;23(1):65-134. doi: 10.1017/S0954422410000041. Epub 2010 Jun 22. Nutr Res Rev. 2010. PMID: 20565994 Review. - A place for dietary fibre in the management of the metabolic syndrome.
Delzenne NM, Cani PD. Delzenne NM, et al. Curr Opin Clin Nutr Metab Care. 2005 Nov;8(6):636-40. doi: 10.1097/01.mco.0000171124.06408.71. Curr Opin Clin Nutr Metab Care. 2005. PMID: 16205465 Review.
Cited by
- Potential Role of Phytochemicals as Glucagon-like Peptide 1 Receptor (GLP-1R) Agonists in the Treatment of Diabetes Mellitus.
Abiola JO, Oluyemi AA, Idowu OT, Oyinloye OM, Ubah CS, Owolabi OV, Somade OT, Onikanni SA, Ajiboye BO, Osunsanmi FO, Nash O, Omotuyi OI, Oyinloye BE. Abiola JO, et al. Pharmaceuticals (Basel). 2024 Jun 5;17(6):736. doi: 10.3390/ph17060736. Pharmaceuticals (Basel). 2024. PMID: 38931402 Free PMC article. Review. - Gut Microbiota Metabolite Messengers in Brain Function and Pathology at a View of Cell Type-Based Receptor and Enzyme Reaction.
Lee B, Lee SM, Song JW, Choi JW. Lee B, et al. Biomol Ther (Seoul). 2024 Jul 1;32(4):403-423. doi: 10.4062/biomolther.2024.009. Epub 2024 Jun 20. Biomol Ther (Seoul). 2024. PMID: 38898687 Free PMC article. Review. - The enteroendocrine axis and its effect on gastrointestinal function, nutrition, and inflammation.
Philpott JD, Rodriguez Hovnanian KM, Stefater-Richards M, Mehta NM, Martinez EE. Philpott JD, et al. Curr Opin Crit Care. 2024 Aug 1;30(4):290-297. doi: 10.1097/MCC.0000000000001175. Epub 2024 Jun 13. Curr Opin Crit Care. 2024. PMID: 38872371 Review. - Dietary impact on fasting and stimulated GLP-1 secretion in different metabolic conditions - a narrative review.
Huber H, Schieren A, Holst JJ, Simon MC. Huber H, et al. Am J Clin Nutr. 2024 Mar;119(3):599-627. doi: 10.1016/j.ajcnut.2024.01.007. Epub 2024 Jan 11. Am J Clin Nutr. 2024. PMID: 38218319 Free PMC article. Review. - Crosstalk between glucagon-like peptide 1 and gut microbiota in metabolic diseases.
Zeng Y, Wu Y, Zhang Q, Xiao X. Zeng Y, et al. mBio. 2024 Jan 16;15(1):e0203223. doi: 10.1128/mbio.02032-23. Epub 2023 Dec 6. mBio. 2024. PMID: 38055342 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical